L-carnitine in Modulating Pain and Inflammation in Rheumatoid Arthritis
NCT ID: NCT05792527
Last Updated: 2023-03-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
46 participants
INTERVENTIONAL
2023-03-05
2026-03-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
L-carnitine Supplementation in Rheumatoid Arthritis Patients
NCT06753565
Outcomes of Biological Therapy on Rheumatoid Arthritis
NCT05267431
Role of L-Arginine Supplementation in the Treatment of Rheumatoid Arthritis
NCT04535427
Assessment of Nutritional Status in Rheumatic Diseases and Association to Disease Activity
NCT07277491
Effect of Laser Puncture on Rheumatoid Arthritis Patients
NCT04684693
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
control group
this group will include 23 patients which will receive the traditional therapy of RA for 3 months.
No interventions assigned to this group
L-carnitine group
this group will include 23 patients which will receive 500mg L-carnitine two times daily after meal plus the traditional therapy of RA for 3 months.
L-carnitine
One 500 mg tablet twice daily after meals
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
L-carnitine
One 500 mg tablet twice daily after meals
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients receive the conventional DMARDs
* Both sexes.
* Age range between 18 and 70 years old.
Exclusion Criteria
* Patients with renal and hepatic dysfunction.
* Patients receiving biological DMARDs.
* Patients receiving oral prednisolone greater than 15 mg/day.
* Patients with hypersensitivity to study medications.
* Patients using antioxidants.
* Pregnant and lactating females.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tanta University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Abdallah Abo-Elazm Shebl Eldisouky
principal investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta university
Tanta, Gharbia Governorate, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
L-carnitine in RA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.